Computed Tomography Densitometry as a Marker of Disease Severity in SSc-ILD
Computed tomography densitometry may serve as an additional marker of disease severity in interstitial lung disease.
Restrictive Lung Disease
RESTRICTIVE LUNG DISEASE
FEATURED
LATEST FEATURES
Homocitrullination May Be Linked to Interstitial Lung Disease in Rheumatoid Arthritis
A link between homocitrullination and the development of interstitial lung disease in patients with rheumatoid arthritis may exist.
Large Clinical Trial to Evaluate Ambulatory Oxygen Is Feasible in Interstitial Lung Disease
The results of a pilot study have demonstrated feasibility of conducting a large clinical trial in patients with fibrotic interstitial lung disease.
Ofev Approved for Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype
The FDA has approved Ofev (nintedanib; Boehringer Ingelheim) for the treatment of patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
LATEST NEWS
Circulating mtDNA Is a Promising Biomarker in Idiopathic Pulmonary Fibrosis
An increase in circulating serum mitochondrial DNA is associated with worse survival in patients with newly diagnosed idiopathic pulmonary fibrosis.
BMI, Changes in Weight Linked to Mortality in Fibrotic Interstitial Lung Disease
Both body mass index and changes in weight have been linked to 1-year mortality risk in patients with fibrotic interstitial lung disease.
Pirfenidone Gets Breakthrough Therapy Status for Unclassifiable Interstitial Lung Disease
Pirfenidone is currently marketed as Esbriet for the treatment of idiopathic pulmonary fibrosis in adults.
Interstitial Lung Abnormalities, Disease More Likely in People With HIV
Individuals with HIV were more likely to have interstitial lung abnormalities and findings suspicious for the presence of interstitial lung disease than individuals without HIV.
Thrombomodulin Alfa Not Recommended for Idiopathic Pulmonary Fibrosis
Use of thrombomodulin alfa for the treatment of acute exacerbation of idiopathic pulmonary fibrosis is not recommended, according to phase 3 clinical trial results.
Idiopathic Pulmonary Fibrosis Annualized Costs Totals More Than $10,000 Per Patient
Patients with idiopathic pulmonary fibrosis are faced with a heavy economic burden, with mean annual costs for admission and inpatient care totaling more than $10,000 per patient.
Idiopathic Pulmonary Fibrosis Susceptibility Identified Via Genomic Markers
Altered expression of 14 genes in adults was associated with idiopathic pulmonary fibrosis susceptibility.
Chronic Viral Infection May Increase Idiopathic Pulmonary Fibrosis Risk
Persistent or chronic, but not acute, viral infections significantly increase the risk of developing idiopathic pulmonary fibrosis.
Want to read more?
Please login or register first to view this content.
Next post in Restrictive Lung Disease
